Incyte Corp

Затворен

СекторЗдравеопазване

127.82 -0.37

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

124.73

Максимум

129.33

Ключови измерители

By Trading Economics

Приходи

282M

586M

Продажби

401M

1.7B

P/E

Средно за сектора

15.697

56.659

EPS

2.8

Марж на печалбата

34.982

Служители

2,844

EBITDA

384M

752M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+4.62% upside

Дивиденти

By Acuity

Следващи печалби

27.10.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

1.2B

25B

Предишно отваряне

128.19

Предишно затваряне

127.82

Настроения в новините

By Acuity

48%

52%

135 / 340 Класиране в Healthcare

Incyte Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.09.2026 г., 23:16 ч. UTC

Incyte Corp shares are trading higher in after-market hours, amid a weaker-than-expected ADP payrolls report that may influence Federal Reserve interest rate decisions.

1.09.2026 г., 22:06 ч. UTC

Incyte Corp shares are higher in after-market hours, though no specific news explains the movement. Broader market pressures persist from rising bond yields.

31.08.2026 г., 20:04 ч. UTC

News

Incyte Corp shares are lower amid broader market weakness following comments from Warsh at the Jackson Hole Economic Symposium on inflation and monetary policy.

28.08.2026 г., 23:21 ч. UTC

News

Incyte Corp shares are lower in after-market trading, continuing a trend of four consecutive sessions finishing down amid rising Treasury yields and mixed ESMO data sentiment.

27.08.2026 г., 20:07 ч. UTC

News

Incyte Corp shares are lower today, reflecting broader market declines. Analysts from TD Cowen upgraded the stock to a strong buy amid ongoing positive sentiment.

26.08.2026 г., 19:36 ч. UTC

Incyte Corp shares are lower during Wednesday's session, having reached a session low earlier. No specific news was identified to explain the price movement.

25.08.2026 г., 23:21 ч. UTC

Incyte Corp. shares are trading roughly flat in after-market hours. Market sentiment is influenced by a decline in crude oil prices and easing treasury yields.

24.08.2026 г., 23:01 ч. UTC

Incyte Corp shares are higher in after-market trading, significantly above their 20-day moving average and near the upper end of their one-month range.

21.08.2026 г., 19:46 ч. UTC

News

Incyte Corp's stock is higher today, supported by President Pablo J. Cagnoni's recent sale of 10,801 shares at $125.56. The stock remains near its one-month high.

20.08.2026 г., 23:41 ч. UTC

Incyte Corp shares are higher in after-market trading, recovering from a slight dip and positioned above the 20-day moving average. No specific news was identified.

19.08.2026 г., 23:01 ч. UTC

Incyte Corp shares declined in after-hours trading, pulling back from earlier gains. The stock remains above its 20-day moving average and near a one-month high.

17.08.2026 г., 20:06 ч. UTC

News

Piper Sandler raised Incyte Corp's price target to $130 from $110, contributing to the stock's upward movement after four days of declines.

14.08.2026 г., 19:36 ч. UTC

Incyte Corp shares are lower, continuing a recent decline amid concerns over July retail sales, which fell 0.6% against expectations for growth.

13.08.2026 г., 23:26 ч. UTC

Incyte Corp shares are lower in after-market hours, despite broader market gains from reduced Federal Reserve rate hike expectations. No specific news was identified.

10.08.2026 г., 19:36 ч. UTC

Incyte Corp shares are higher today, maintaining an upward trend since Friday. The stock remains above its 20-day moving average, reflecting solid performance.

6.08.2026 г., 19:44 ч. UTC

Incyte Corp shares are lower amid broader biotechnology sector declines. The stock is trading near the lower end of its one-month range.

5.08.2026 г., 19:56 ч. UTC

Incyte Corp shares are lower today, retracing from earlier session gains. No specific news was identified to explain the decline.

4.08.2026 г., 19:46 ч. UTC

News

Mizuho raised its price target on Incyte Corp to $137, maintaining an Outperform rating. Analyst Josh Brown's comments on CNBC contributed to positive sentiment today.

3.08.2026 г., 23:56 ч. UTC

Incyte Corp shares are higher in after-market hours, recovering from five consecutive daily declines. Broader market sentiment remains positive amid declining oil prices.

31.07.2026 г., 22:21 ч. UTC

Incyte Corp's shares are higher in after-market trading, driven by a rise in the Biotechnology sub-sector. The stock remains above its 20-day moving average.

30.07.2026 г., 23:56 ч. UTC

Incyte Corp shares are lower in after-market trading, continuing a trend of declines since Thursday's close amid broader market pressures.

29.07.2026 г., 22:51 ч. UTC

Event

Incyte Corp shares are higher after the European Commission approved Opzelura® for moderate atopic dermatitis treatment. Market conditions are also advancing in after-market trading.

28.07.2026 г., 23:02 ч. UTC

Incyte Corp shares are lower in after-market hours amid a broader market decline influenced by concerns over technology stocks and geopolitical tensions.

27.07.2026 г., 23:02 ч. UTC

Incyte Corp shares are lower in after-market hours, following a decline earlier in the session amid broader market sentiment influenced by falling crude oil prices.

24.07.2026 г., 21:01 ч. UTC

Incyte Corp shares are lower in after-market hours, with no specific news identified. Broader market sentiment was affected by a sharp Nasdaq decline.

22.07.2026 г., 20:04 ч. UTC

Incyte Corp's shares are lower today, continuing a decline since Tuesday. The stock remains above its 20-day moving average and near the upper end of its one-month range.

21.07.2026 г., 16:36 ч. UTC

Social Media
News

HC Wainwright reiterated its Buy rating on Incyte Corp with a $140 price target, contributing to gains in Incyte shares during Tuesday's session.

20.07.2026 г., 21:56 ч. UTC

Incyte Corp shares are lower in after-market hours following a volatile session, despite trading above the 20-day moving average and near a one-month high.

17.07.2026 г., 23:16 ч. UTC

Incyte Corp shares are higher in after-market trading, continuing a trend of five consecutive sessions of gains. No specific news was identified for the movement.

16.07.2026 г., 23:06 ч. UTC

Incyte Corp shares are trading lower in after-market hours amid a broader market decline, influenced by rising interest rates and geopolitical tensions.

Сравнение с други в отрасъла

Ценова промяна

Incyte Corp Прогноза

Ценова цел

By TipRanks

4.62% нагоре

12-месечна прогноза

Среден 130.79 USD  4.62%

Висок 155 USD

Нисък 104 USD

Според 21 анализатори от Wall Street, предложили 12-месечна ценова цел за Incyte Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

21 ratings

11

Купи

10

Задържане

0

Продай

Настроение

By Acuity

135 / 340 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
help-icon Live chat